Ratings Yidu Tech Inc.

Equities

2158

KYG9845C1069

Market Closed - Hong Kong S.E. Other stock markets 04:08:22 2024-05-10 am EDT			5-day change	1st Jan Change
4.28 ^HKD	0.00%		-2.73%	-15.42%

Apr. 12	Yidu Tech Inc. commences an Equity Buyback Plan for 105,285,814 shares, representing 10% of its issued share capital, under the authorization approved on September 28, 2023.	CI
Jan. 23	Yidu Tech Affiliate Wins Bid for Information Platform for Chaozhou City Medical Group	MT

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

Strengths

Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
Thanks to a sound financial situation, the firm has significant leeway for investment.
With regards to fundamentals, the enterprise value to sales ratio is at 1.21 for the current period. Therefore, the company is undervalued.
The company's share price in relation to its net book value makes it look relatively cheap.
For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
Analysts covering this company mostly recommend stock overweighting or purchase.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
Low profitability weakens the company.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Sector: Advanced Medical Equipment & Technology

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
YIDU TECH INC.	-15.42%	582M		-
VEEVA SYSTEMS INC.	+5.85%	32.93B		C
PRO MEDICUS LIMITED	+20.16%	7.94B		C-
SECTRA AB	+30.81%	4.19B		B-
EVOLENT HEALTH, INC.	-25.95%	2.8B		C-
OMNICELL, INC.	-19.96%	1.38B		B
LUNIT INC.	-31.87%	1.17B		-
SIMULATIONS PLUS, INC.	+8.02%	966M		C
B-SOFT CO.,LTD.	-35.73%	900M		-
VERADIGM INC.	-25.74%	839M	-	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes